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their ability to inhibit hepatitis C virus (HCV) replication in acutely infected Huh7.5 cells. Most of the substituted
N-aryl benzamide compounds showed convincing anti-HCV activities. Compounds 1f, 1g and 4c exhibited
potent anti-replicative activity at low micromolar levels (IC50¼1.0–2.0 μM) with selective indices (SI) greater
than 40. Mechanistic analysis indicated that the active compounds increased intracellular hA3G protein levels and
inhibited HCV replication in a dose-dependent manner. The results demonstrate that this series of substituted N-
aryl benzamide compounds warrant further investigation as inhibitors of HCV replication.
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Figure 2 Chemical optimization of IMB-26.
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Over 170 million people worldwide are infected with the hepatitis
C virus (HCV), and many of those are at risk of developing liver
cirrhosis and hepatocellular carcinoma1,2. Moreover, the aging of
this cohort will result in HCV-related-mortality increasing for
future decades3. At present no vaccine is available to prevent HCV
infection, and antiviral chemotherapy is an important approach to
prevent this projected health burden. Unfortunately, the current
classical combination of antiviral therapy with PEG-interferon
(PEG-IFN) and ribavirin is effective in only 40–50% of patients
who are infected with HCV genotype 1, and causes treatment-
limiting side effects4,5. Medicinal scientists have made great
progress in the development of novel HCV chemotherapy agents.
Both long-lasting interferon and ribavirin derivatives are in
development to improve efﬁcacy and tolerability of PEG-IFN/
ribavirin therapy6–8. Moreover, novel direct-acting antiviral agents
that speciﬁcally target the HCV life cycle have been successfully
developed9–12. Two HCV NS3/4A protease inhibitors telaprevir
and boceprevir (Fig. 1) were approved for treatment of HCV
infection by the United States Food and Drug Administration in
201113,14. Addition of telaprevir or boceprevir to PEG-IFN and
ribavirin signiﬁcantly increased the therapeutic efﬁcacy and
shortened the duration of therapy in patients with HCV genotype
1. However, this combination was still unsatisfactory for the
therapeutic needs of HCV non-1 genotype patients and those
patients with contraindications to PEG-IFN or ribavirin therapy.
Furthermore, HCV could easily acquire resistance to protease
inhibitors through mutation15,16. Therefore, new anti-HCV agents
with novel mechanisms of action are needed17–19.
In our previous study, the small compound IMB-26 (3, 4,
5-trimethoxyphenyl 3-(2-bromopropionamido)-4-methoxybenza-
mide, Fig. 2) was identiﬁed as a stabilizer of human apolipoprotein
B mRNA-editing enzyme catalytic polypeptide-like 3G (hA3G).
hA3G was a restrictive cellular factor for HCV and HIV-1
replication20,21. IMB-26 was effective against both HCV and
HIV-1 in vitro22. The simple structure of IMB-26 was distinct
from current HCV inhibitors. Its novel antiviral mechanism as
an hA3G stabilizer, coupled with the current deﬁciency of
available HCV chemotherapeutics prompted us to seek novel
HCV inhibitors using IMB-26 as starting point. IMB-26 exhibited
cytotoxicity, likely due to the presence of an α-bromocarbonyl
group, which resulted in a lower selective index (SI¼7.1). To ﬁnd
more active and less toxic compounds against HCV, 28 substituted
N-(hetero)arylbenzamide/benzenesulfonamide analogs of IMB-26
were designed, synthesized and evaluated for their inhibitory
activities against HCV replication in cultured Huh7.5 cell lines.
Their structure–activity relationships (SAR) and mechanisms of
action against HCV replication were investigated in this study.N
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Figure 1 The chemical structures of HCV NS32. Results and discussion
2.1. Synthesis
In this paper, the structures of the synthesized compounds are
summarized as the general formula I (Fig. 2), with alterations in the
following fragments of IMB-26: (a) substitutions to ring A and B; (b)
alterations to the amide linker between two benzene rings; (c) changes
to ring B. Compound 4 was commercially available. The detailed
synthesis of compounds 4b, 4c, 1k and 3 was previously reported23.
Brieﬂy, amino or hydroxyl acylation of the starting material 3-amino-4-
methoxybenzoric acid (S1), 3-hydroxy-4-methoxybenzoric acid (S2) or
3-amino-4-chlorobenzoric acid (S3) was undertaken to afford inter-
mediates M1-1–M1-3, M2 and M3, respectively. Products 1a–1l, 2
and 3 were prepared by coupling various anilines or phenols with
above intermediates using diisopropylcarbodiimide (DIC) as a coupling
agent and N-hydroxybenzotriazole (HOBt) as an activation agent in
dried dimethylformamide (DMF) with yields of 38–63%, as shown in
Scheme 1. Commercially available compound 4 was mixed with
different propionyl chlorides in tetrahydrofuran (THF) to give sub-
stituted benzanilide products 4a–4c (Scheme 1).
N-arylbenzamides 1m–1o and N-heteroarylbenzamides 1p–1r
were synthesized starting from 3-nitro-4-methoxybenzoic acid (S4)
using the method shown in Scheme 2. 3-Nitro-4-methoxybenzoic
acid (S4) was ﬁrst converted into the acid chloride to easily generate
nitrated intermediates M4-1–M4-3, which were reduced by hydro-
genation to form the corresponding aminated intermediatesM4-4–M4-
6. Amino acylation produced the ﬁnal products 1m–1r with a total
yield greater than 20%. Using a similar method, the nitrated
intermediates M5-1 and M5-2, aminated intermediates M5-3 and
M5-4, and N-(hetero)aryl benzenesulfonamide products 5a–5d were
prepared from nitro-substituted benzosulfonic acid (S5) with a total
yield of 24–66%. Phenyl benzenesulfonamide (6) was also obtained by
the same method starting from 3-amino-4-methoxybenzenesulfonic
acid (S6) working through intermediate M6.2.2. Structure–activity relationship (SAR) analysis
All compounds were tested for antiviral activity using HCV-
infected Huh7.5 cells with INF-α as a positive control. TotalH
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Scheme 2 Synthesis routes of N-(hetero)aryl benzamide compounds 1m–1r, N-(hetero)aryl benzenesulfonamide compounds 5a–5d and 6.
Reagents and conditions: (a) SOCl2, room temperature or reﬂux; (b) substituted arylamine, TEA or NaH, THF; (c) H2, Pd/C, 50 barr; (d)
acylchloride or iodomethane, triethylamine, DCM.
Y. Li et al.314intracellular HCV RNA was quantiﬁed using a one-step RT-PCR to
calculate the IC50 of test compounds by dose-response evaluation.
In Table 1, 1a, 1b were ﬁrstly synthesized with the expectation that
removal of the bromo-substitution on IMB-26 would decrease
cytotoxicity. This resulted in 3–6 fold increases in the selective
index (SI420) due to comparative antiviral activity (IC50¼3.2 μM
and 6.4 μM for 1a and 1b, respectively) and signiﬁcant lower
cytotoxicity (CC50¼150 μM and 137 μM respectively) compared toIMB-26 (IC50¼2.1 μM, CC50¼15 μM). Substitution of the C3-N-
propionyl group with C3-O-propionyl or C3-N-triﬂuoroacetyl group
led to decreased antiviral activity (6.4 μMoIC50o71 μM for 1b, 1n
and 2). The absence of a carbonyl side-chain on the amino group of
the A ring (4) signiﬁcantly decreased antiviral activity about 10-fold
relative to compounds 4a–4c, where a carbonyl was present. The
relative activity of compounds 4a–4c also indicated that the C3-N-
propionyl group was a preferred substituent. As we predicted, all
Table 1 Structure–activity relationship for C3 substituent and ring B.
HN
R1
H3CO
O
R2
Compd.a R1 R2 CC50 (μM) IC50 (μM) SI
IMB-26 –NHCOCH(Br)CH3 3,4,5-OCH3-phenyl 1571.1 2.170.40 7.1
1a –NHCOCH2CH3 3,4,5-OCH3-phenyl 150750 3.270.53 47
1b –NHCOCF3 3,4,5-OCH3-phenyl 137733 6.470.59 21
2 –OCOCH2CH3 3,4,5-OCH3-phenyl 6777.5 8.171.5 8.3
1n –NHCOCF3 4-CF3-phenyl >492 7176.2 >6.9
1o –NHCOCH(Br)CH3 4-CF3-phenyl 9.171.7 3.770.4 2.4
4 –NH2 phenyl 693740 41717 17
4a –NHCOCH(Br)CH3 phenyl 1171.1 4.470.73 2.5
4b –NHCOCH(Cl)CH3 phenyl 69710 4.670.75 15
4c –NHCOCH2CH3 phenyl 128717 1.870.00 72
1p –NHCOCH(Br)CH3 4,6-OCH3-pyrimidin-2-yl 2970.50 1472.7 2.1
1q –NHCOCH2CH3 4,6-OCH3-pyrimidin-2-yl 416747 1570.61 27
1r –NHCOCH2CH3 5-CN-pyridin-2-yl 484717 1974.7 24
aINF-α showed IC50 of 0.3170.06 μg/mL as the positive control in this test.
Table 2 Substituent effects in ring B.
HN
NH
H3CO R
O
O
Compd. R CC50 (μM) IC50
(μM)
SI
1a 3,4,5-OCH3 150750 3.270.53 47
1f 4-OCH3 208716 1.970.57 108
1g 3-OCH2CH2O-4 4575.4 1.070.05 44
1h 4-CH3 7572.2 2.270.19 33
1i 4-Cl 13473.6 4.670.21 29
1j 4-F 134724 1171.8 12
1l 2,4-Cl 197715 1673.0 11
1m 4-CF3 431716 1770.02 25
4c H 128717 1.870.00 72
Synthesis of novel substituted N-aryl benzamides as hA3G stabilizers and their inhibitory activities against hepatitis 315synthesized compounds (1o, 1p and 4a) with an α-bromocarbonyl
group at the C3-position of ring A exhibited no antiviral selectivity
(SIo5) due to their cytotoxicity in Huh7.5 cells. Meanwhile, when
ring B was changed from substituted phenyl into heteroaryl group,
the antiviral activity was decreased several fold (14 μMoIC50o19
μM for 1p, 1q, 1r).
To investigate the importance of trimethoxyl substitution on the
ring B, compounds with a single methoxyl substitution at the C4-
position of ring B (1f) were synthesized and are shown in Table 2.
Compound 1f exhibited slightly higher antiviral activity (IC50¼1.9
μM) than trimethoxyl substituted compound 1a, and had an SI value
of 108. Compounds with diverse substitutions on ring A (1g–1m)
were synthesized and showed clear antiviral activities (Table 2).
Compounds with an electron-withdrawing substitution (1i, 1j, 1l and
1m) showed weaker anti-HCV activity than compounds with an
electron-donating substitution (1f, 1g, 1h). Among those compounds,compound 1g with a dioxyethylene group substitution exhibited the
most potent inhibitory activity (IC50¼1.0 μM, SI¼44). Compound
4c without a substitution in ring B had a comparable antiviral ability
to compound 1g with a higher SI (IC50¼1.8 μM, SI¼72).
In Table 3, replacing the amide linker between ring A and B of
compounds 1a, 1b, 1f and 4c with an ester linker or N-CH3 amide
linker led to 1c–1e and 1k with 3–16-fold decreases in antiviral
potency. The replacement of amide linker between ring A and B with
sulfonamide linker 6 (IC50¼18 μM) also resulted in about 4-fold
lower HCV inhibition compared to corresponding compound 1i
(IC50¼4.6 μM). When the methoxyl group at the C4-position of ring
A in the benzenesulfonamide compounds was simultaneously replaced
with methyl group, almost complete loss of antiviral activity was
observed for compounds 5a–5d. Taken these together, these results
indicated that the NH of the amide linker and the C4–OCH3 group
made contributions to the antiviral activity of these compounds, while a
hydrophilic sulfonamide linker was unfavorable to antiviral activity.
Moreover, loss activity of compound 3 with a chloro instead of
methoxyl substitution (4c) at C4-position of ring A also conﬁrmed the
importance of the methoxyl group.
2.3. Effects of compound 1g on intracellular hA3G expression
and HCV NS3 synthesis
The most active compound 1g was chosen to explore the
mechanism of action of these inhibitors by immunoblot measure-
ment. The expression of intracellular hA3G protein and HCV NS3
protein were measured in the Huh7.5 cells with or without
treatment of the test compound. Compound 1g treatment produced
higher intracellular hA3G protein levels (Fig. 3A) and lower HCV
NS3 protein levels (Fig. 3B). These effects were dose-dependent.3. Conclusions
The present study identiﬁed several novel substituted N-aryl benzamide
compounds that displayed potent anti-HCV activity at low micromolar
levels. The pharmacophore of N-aryl-(3-amide-4-methoxy)benzamide
Table 3 SAR for C4 substituent and linker.
X
Y R3
R2
R1
Compd. R1 R2 X Y R3 CC50 (μM) IC50 (μM) SI
1a OCH3 –NHCOCH2CH3 C(O) NH 3,4,5-OCH3-phenyl 150750 3.270.53 47
1b OCH3 –NHCOCF3 C(O) NH 3,4,5-OCH3-phenyl 137733 6.470.59 21
1c OCH3 –NHCOCH2CH3 C(O) O 3,4,5-OCH3-phenyl 194712 1170.02 17
1d OCH3 –NHCOCF3 C(O) O 3,4,5-OCH3-phenyl 133711 1970.34 7.0
1e OCH3 –NHCOCH2CH3 C(O) O 4-OCH3-phenyl 27973.9 1874.2 15
1f OCH3 –NHCOCH2CH3 C(O) NH 4-OCH3-phenyl 208716 1.970.57 108
1k OCH3 –NHCOCH2CH3 C(O) N(CH3) phenyl >320 29 411
3 Cl –NHCOCH2CH3 C(O) NH phenyl 49 NA /
4c OCH3 –NHCOCH2CH3 C(O) NH phenyl 128717 1.870.00 72
5a CH3 –NHCH3 –S(O)2– NH 3,4,5-OCH3-phenyl 91719 NA /
5b CH3 –NHCOCH3 –S(O)2– NH 3,4,5-OCH3-phenyl 94712 120732 /
5c CH3 –NHCOCH2CH3 –S(O)2– NH 3,4,5-OCH3-phenyl 172734 NA /
5d CH3 –NHCOCH2CH3 –S(O)2– NH 4,6-OCH3-pyrimidin-2-yl >525 NA /
1i OCH3 –NHCOCH2CH3 C(O) NH 4-Cl-phenyl 13473.6 4.670.21 29
6 OCH3 –NHCOCH2CH3 –S(O)2– NH 4-Cl-phenyl 10178.9 1879.7 5.6
NA: not active.
1g (μM) 28 14 7.0 0 
hA3G 
Actin 
hA3G/ Actin 1.95 1.84 1.69 1.00 
1g (μM) 28 14 7.0 3.5 0 
HCV NS3 
Actin 
HCV NS3/ Actin 0.03 0.08 0.22 0.49 1.00 
Figure 3 Effects of compound 1g on the HCV replication. (A)
Intracellular hA3G protein level elevated dose-dependently after 24 h
treatment of 1g in naive Huh7.5 cells. (B) HCV NS3 protein synthesis
dose-dependently decreased after 72 h treatment of 1g in HCV-
infected Huh7.5 cells.
Y. Li et al.316was revealed by SAR analysis. An increase in intracellular hA3G
levels and a decrease in HCV NS3 protein levels was observed after
treatment with active compounds. Although the antiviral activity was
not comparable to that of current protease inhibitors, this series of
substituted N-aryl benzamides deserves further research as potentially
therapeutic HCV inhibitors because of their novel mechanism of action
and possible lower susceptibility to developed drug-resistance. Further
optimization should produce more potent compounds; we anticipate
that hA3G regulators could provide a new approach to HCV
chemotherapy.4. Experimental section
4.1. Chemistry
Melting points (Mp) were determined using an X6 microscope
melting point apparatus and were uncorrected. 1H NMR and13C NMR spectra were recorded using a Varian Mercury-400 or
500 MHz spectrometer in CDCl3 or DMSO-d6 solutions at room
temperature with TMS as an internal standard, and HRMS (high
resolution mass spectra) were recorded on an Autospec Ultima-
TOF mass spectrometer. Start materials S1, S2, S3, S4, S5 S6 and
compound 4 were purchased from J&K Chemicals. Compounds
4b, 4c, 1k and 3 were previously reported23. HPLC analysis was
performed on a SHIMADZU LC-10ATvp instrument equipped
with a UV detector. Detector wavelength: 260 nm. Column:
PARTISIL♯ ODS 5 μm, 250 mm 4.6 mm (Dikma Technologies),
Mobile phase: acetonitrile/water¼65/35. The ﬂow rate was
1.0 mL/min. HPLC purity of all product compounds was 495%.4.2. General procedure for the synthesis of compounds
1a–1l, 2 and 3
Step 1: To a solution of substituted benzoic acid (2.0 mmol) and
TEA (2.5 mmol, 1.25 equiv.) in THF (50 mL) was added acyl
chloride or anhydride (3.0 mmol, 1.5 equiv.) while on an ice bath,
and the reaction was stirred at room temperature after addition
under nitrogen until completion (6–8 h). The reaction was mon-
itored by TLC (10% DCM/methanol). The solvent was evaporated
in vacuo. The residue was dissolved in DCM which was washed
with 0.5 M HCl (25 mL) followed by water. The organic phase
was concentrated and dispersed in ether (80 mL), and the insoluble
substance was ﬁltered to give the crude intermediate M1–M3.4.2.1. 3-(2-Bromo)propionamido-4-methoxybenzoic acid (M1-1)
Reaction of 3-amino-4-methoxybenzoic acid (S1) with 2-
bromopropionyl chloride afforded intermediate M1-1 as off-
white solid in 77% yield. 1H NMR (400 MHz, DMSO-d6): δ
1.72 (d, J¼6.8 Hz, 3H), 3.91 (s, 3H), 5.04 (q, J¼6.8 Hz, 1H),
7.14 (d, J¼8.8 Hz, 1H), 7.72 (dd, J1¼8.8 Hz, J2¼2.4 Hz, 1H),
8.57 (d, J¼2.0 Hz, 1H), 9.657 (s, 1H, NH), 12.670 (br, 1H). MS
(ESI): m/z 301.1 [M+H]+.
Synthesis of novel substituted N-aryl benzamides as hA3G stabilizers and their inhibitory activities against hepatitis 3174.2.2. 3-Propionamido-4-methoxybenzoic acid (M1-2)
Reaction of S1 with propionyl chloride afforded intermediate M1-
2 as off-white solid in 91% yield. 1H NMR (500 MHz, DMSO-d6):
δ 1.06 (t, J¼7.5 Hz, 3H), 2.39 (q, 2H, J¼7.5 Hz), 3.89 (s, 3H),
7.10 (d, J¼8.0 Hz, 1H), 7.67 (d, J¼7.5 Hz 1H), 8.56 (s, 1H), 9.12
(s, 1H), 12.59 (br, 1H). MS (ESI): m/z 224.0 [M+H]+.
4.2.3. 3-Triﬂuoroacetamido-4-methoxybenzoic acid (M1-3)
Reaction of S1 with triﬂuoroacetyl anhydride afforded intermedi-
ate M1-3 as off-white solid in 78% yield. 1H NMR (400 MHz,
DMSO-d6): δ 3.89 (s, 3H), 7.23 (d, J¼8.8 Hz, 1H), 7.90 (dd,
J1¼8.8 Hz, J2¼1.6 Hz, 1H), 7.96 (d, J¼2.0 Hz, 1H), 10.79 (br,
1H), 12.79 (s, 1H). MS (ESI): m/z 286.0 [M+Na]+.
4.2.4. 4-Methoxy-3-(propionyloxy)benzoic acid (M2)
Reaction of 3-hydroxyl-4-methoxybenzoic acid (S2) with propio-
nyl chloride afforded M2 as white solid in 72% yield. 1H NMR
(400 MHz, DMSO-d6): δ 1.07 (t, J¼7.6 Hz, 3H), 2.42 (q, J¼7.6
Hz, 2H), 3.83 (s, 3H), 7.68 (m, 2H), 8.56 (s, 1H), 12.74 (s, 1H).
MS(ESI): m/z 225 [M+H]+.
4.2.5. 4-Chloro-3-propionamidobenzoic acid (M3)
Reaction of 3-amino-4-chlorobenzoic acid (S3) with propionyl
chloride afforded intermediate M3 as white solid in 70% yield.
1H NMR (400 MHz, DMSO-d6): δ 1.07 (3H, t, J¼7.6 Hz), 2.42
(2H, q, J¼7.6 Hz), 7.11 (1H, d, J¼8.8 Hz), 7.68 (1H, m), 8.56
(1H, d, J¼8.8 Hz), 9.12 (1H, s, NH), 12.59 (1H, s). MS (ESI): m/z
228 [M+H]+.
Step 2: To a solution of the above crude intermediates
(2.0 mmol) in DMF (10 mL), HOBt (2.3 mmol) and DIC
(2.3 mmol) in 10 mL of DMF were added substituted aniline or
phenol (2.5 mmol) with stirring at room temperature. The reaction
mixture was stirred for 8 h and rinsed with 0.5 M aqueous NaOH
solution and water. The organic phase was concentrated and
puriﬁed by silica gel chromatography and eluted with a solution of
DCM/methanol (20/1) to afford the ﬁnal products as white or off-
white solids.
4.2.6. 3′,4′,5′-Trimethoxyphenyl 3-propionamido-4-
methoxybenzamide (1a)
Reaction of M1-2 with 3,4,5-trimethoxybenzenamine afforded
product 1a as white solid. Yield, 48%. Mp: 81–83 1C. 1H NMR
(400 MHz, CDCl3), δ: 1.3 (s, J¼7.6 Hz, 3H), 2.5 (q, J¼7.6 Hz,
2H), 3.82 (s, 3H), 3.9 (s, 6H), 3.95 (s, 3H), 6.99 (s, 2H), 7.01 (d,
J¼8.8 Hz, 1H), 7.78 (dd, J1¼7.6 Hz, J2¼2.0 Hz, 1H), 7.85 (br,
2H), 8.9 (d, J¼1.6 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ
172.48, 164.99, 153.26 (2C), 150.28, 134.64, 134.29, 127.26 (2C),
124.89, 116.61, 110.19, 97.92 (2C), 60.97, 56.41 (2C), 56.03,
31.03, 9.56; HR-MS (ESI): m/z calcd. for C20H25N2O6 389.17126,
found: 389.17327 [M+H]+.
4.2.7. 3′,4′,5′-Trimethoxyphenyl 3-triﬂuoroacetamido-4-
methoxybenzamide (1b)
Reaction of M1-3 with 3,4,5-trimethoxybenzenamine afforded
product 1b as white solid. Yield, 25%. Mp: 142-144 1C.
1H NMR (400 MHz, CDCl3): δ 3.84 (s, 9H), 4.0 (s, 3H), 6.97
(s, 2H), 7.03 (d, J¼8.8 Hz, 1H), 7.86 (d, J¼8.8 Hz, 1H), 7.9
(s, 1H), 8.6 (s, 1H), 8.75 (s, 1H); 13C NMR (100 MHz, CDCl3):
δ 164.44, 155.09, 153.31 (2C), 150.86, 134.84, 133.95, 127.61,
126.73 (2C), 124.72, 117.66, 110.55, 97.97(2C), 60.95, 56.36,56.11 (2C); HR-MS (ESI): m/z calcd. for C19H20F3N2O6
429.12735, found: 429.13112 [M+H]+.
4.2.8. 3′,4′,5′-Trimethoxyphenyl 3-propionamido-4-
methoxybenzonate (1c)
Reaction of M1-2 with 3,4,5-trimethoxyphenol afforded product
1c as white solid. Yield, 31%. Mp: 71-73 1C. 1H NMR (400 MHz,
CDCl3): δ 1.3 (s, J¼7.6 Hz, 3H), 2.5 (q, J¼7.6 Hz, 2H), 3.8 (s,
9H), 3.95 (s, 3H), 6.44 (s, 2H), 6.98 (d, J¼8.4 Hz, 1H), 7.76 (br,
1H), 7.9 (dd, J1¼8.4 Hz, J2¼1.6 Hz, 1H), 7.9 (br, 2H), 9.2 (s,
1H); 13C NMR (100 MHz, CDCl3): δ 172.33, 164.94, 156.46,
150.09, 131.15, 127.46, 127.38, 124.64, 122.25 (2C), 116.71,
114.13 (2C), 110.06, 60.97, 56.41 (2C), 56.03, 31.03, 9.56; HR-
MS (ESI): m/z calcd. for C20H24NO7 390.15494, found:
390.15528 [M+H]+.
4.2.9. 3′,4′,5′-Trimethoxyphenyl 3-triﬂuoroacetamido-4-
methoxybenzonate (1d)
Reaction of M1-3 with 3,4,5-trimethoxyphenol afforded product
1d as white solid. Yield, 28%. Mp: 165–166 1C. 1H NMR
(400 MHz, CDCl3): δ 3.85 (s, 9H), 4.0 (s, 3H), 6.46 (s, 2H),
7.05 (d, J¼8.0 Hz, 1H), 8.07 (dd, J1¼8.4 Hz, J2¼2.0 Hz, 1H),
8.54 (s, 1H), 9.12 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 172.00,
165.04, 153.40 (2C), 151.76, 147.11, 135.59, 127.60, 126.76,
122.24, 121.24, 109.51, 99.33 (2C), 60.89, 56.10 (2C), 56.07,
30.94, 23.68, 9.55; HR-MS (ESI): m/z calcd. for C19H19F3NO7
430.11333, found: 430.11136 [M+H]+.
4.2.10. 4′-Methoxyphenyl 3-propionamido-4-methoxybenzonate
(1e)
Reaction of M1-2 with 4-methoxyphenol afforded product 1e as
white solid. Yield, 18%. Mp: 119–122 1C. 1H NMR (400 MHz,
CDCl3): δ 1.27 (t, J¼7.6 Hz, 3H), 2.5 (q, J¼7.6 Hz, 2H), 3.82 (s,
3H), 3.98 (s, 3H), 6.91 (d, J¼8.8 Hz, 2H), 6.96 (d, 1H, J¼8.8
Hz), 7.11 (d, J¼8.8 Hz, 2H), 7.75 (br, 1H), 7.92 (d, J¼8.4 Hz,
1H), 9.21 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 172.16, 162.43,
153.05, 143.52, 128.84, 128.60, 128.28, 127.57, 124.73, 121.25,
120.40, 117.15, 110.04, 108.53, 56.28 (2C), 30.91, 9.46; HR-MS
(ESI): m/z calcd. for C18H20NO5 330.13415, found: 330.13403
[M+H]+.
4.2.11. 4′-Methoxyphenyl 3-propionamido-4-methoxybenzamide
(1f)
Reaction of M1-2 with 4-methoxybenzenamine afforded product
1f as white solid. Yield, 25%. Mp: 175–177 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.07 (t, J¼10.0 Hz, 3H), 2.4 (q,
J¼10.0 Hz, 2H), 3.73 (s, 3H), 3.89 (s, 3H), 6.89 (d, J¼12.0 Hz,
2H), 7.1 (d, J¼12.0 Hz, 1H), 7.6 (d, J¼12.0 Hz, 2H), 7.7 (dd,
J1¼12.0 Hz, J2¼1.2 Hz, 1H), 8.48 (br, 1H), 9.15 (s, 1H), 10.0 (s,
1H); 13C NMR (100 MHz, CDCl3): δ 172.33, 164.94, 156.46,
150.09, 131.15, 127.46, 127.38, 124.64, 122.25 (2C), 116.71,
114.13 (2C), 110.06, 60.97, 56.41 (2C), 56.03, 31.03, 9.56; HR-
MS (ESI): m/z calcd. for C18H21N2O4 329.15013, found:
329.15135 [M+H]+.
4.2.12. 3′,4′-Dioxyethylenephenyl 3-propionamido-4-
methoxybenzamide (1g)
Reaction of M1-2 with 3′,4′-dioxyethylenebenzenamine afforded
product 1g as white solid. Yield, 23%. Mp: 152–154 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.06 (t, J¼7.6 Hz, 3H), 2.39 (q, J¼7.6
Hz, 2H), 3.89 (s, 3H), 4.21 (q, J¼8.8 Hz, 4H), 6.79 (d, J¼8.8 Hz,
Y. Li et al.3181H), 7.12 (d, J¼8.8 Hz, 1H), 7.16 (dd, J1¼8.8 Hz, J2¼2.4 Hz,
1H), 7.34(d, J¼2.4 Hz, 1H), 7.69 (dd, J1¼8.8 Hz, J2¼2.4 Hz),
8.46 (s, 1H), 9.15 (s, 1H), 9.90 (s, 1H); 13C NMR (100 MHz,
CDCl3): δ 172.31, 164.91, 150.12, 143.46, 140.46, 131.78,
127.48, 127.31, 124.67, 117.11, 116.80, 114.11, 110.30, 110.05,
64.41, 64.29, 56.00, 31.01, 9.57; HR-MS (ESI): m/z calcd. for
C19H21N2O5 357.14505, found: 357.14391 [M+H]
+.4.2.13. 4′-Methylphenyl 3-propionamido-4-methoxybenzamide
(1h)
Reaction of M1-2 with 4-methoxybenzenamine afforded product
1h as white solid. Yield, 33%. Mp: 154–156 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.25 (t, J¼7.6 Hz, 3H), 2.31 (s, 3H),
2. 44 (q, J¼7.6 Hz, 2H), 3.92 (s, 3H), 6.93 (d, J¼8.2 Hz, 1H),
7.13 (d, J¼8.0 Hz, 2H), 7.52 (d, J¼8.0 Hz, 2H), 7.75
(d, J¼8.2 Hz, 1H), 7.82 (s, 1H), 8.07 (br, 1H), 8.85 (br, 1H);
13C NMR (100 MHz, CDCl3): δ 172.28, 165.01, 150.12, 135.53,
133.74, 129.34 (2C), 127.43, 127.27, 124.46, 120.34 (2C), 116.97,
109.90, 55.89, 30.88, 20.81, 9.49; HR-MS (ESI): m/z calcd. for
C18H21N2O3 313.15522, found: 313.15349 [M+H]
+.4.2.14. 4′-Chlorophenyl 3-propionamido-4-methoxybenzamide
(1i)
Reaction of M1-2 with 4-chlorobenzenamine afforded product 1i
as white solid. Yield, 35%. Mp: 130–132 1C. 1H NMR (400 MHz,
CDCl3): δ 1.28 (t, J¼7.6 Hz, 3H), 2.48 (q, J¼7.6 Hz, 2H), 3.96
(s, 3H), 6.98 (d, J¼8.4 Hz, 1H), 7.33 (d, J¼8.8 Hz, 2H), 7.61 (d,
J¼8.8 Hz, 2H), 7.77 (dd, J1¼8.4 Hz, J2¼2.0 Hz, 1H), 7.82 (s,
1H), 8.09 (s, 1H), 8.87 (s, 1H); 13C NMR (100 MHz, CDCl3): δ
172.43, 165.26, 150.38, 136.97, 128.88, 128.73 (2C), 127.09,
126.97, 124.87, 121.52 (2C), 117.31, 110.01, 55.93, 26.85, 9.51;
HR-MS (ESI): m/z calcd. for C17H17ClN2NaO3 355.08254, found:
355.08101 [M+Na]+.4.2.15. 4′-Fluorophenyl 3-propionamido-4-methoxybenzamide
(1j)
Reaction of M1-2 with 4-ﬂuorobenzenamine afforded product 1j
as white solid. Yield, 43%. Mp: 167–169 1C. 1H NMR (400 MHz,
CDCl3): δ 1.27 (t, J¼7.6 Hz, 3H), 2. 48 (q, J¼7.6 Hz, 2H), 3.96
(s, 3H), 6.98 (d, J¼8.4 Hz, 1H), 7.04 (t, J¼8.4 Hz, 2H), 7.59 (q,
J1¼8.4 Hz, J2¼4.8 Hz, 2H), 7.80 (dd, J1¼8.4 Hz, J2¼1.6 Hz,
1H), 7.83 (s, 1H), 7.92 (br, 1H), 8.91 (br, 1H); 13C NMR
(100 MHz, CDCl3): δ 172.39, 165.06, 158.21, 150.24, 134.07,
127.40, 127.14, 124.73, 122.26, 122.19, 116.76, 115.69, 115.47,
110.11, 56.03, 31.02, 9.55; HR-MS (ESI): m/z calcd. for
C17H18FN2O3 317.13015, found: 317.12898 [M+H]
+.4.2.16. 2′,4′-Dichlorophenyl 3-propionamido-4-
methoxybenzamide (1l)
Reaction of M1-2 with 2,4-dichlorobenzenamine afforded product
1l as white solid. Yield, 33%. Mp: 159–161 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.07 (t, J¼7.6 Hz, 3H), 2.40 (q, J¼7.6
Hz, 2H), 3.90 (s, 3H), 7.15 (d, J¼8.8 Hz, 1H), 7.45 (dd,
J1¼8.4 Hz, J2¼2.4 Hz, 1H), 7.60 (d, J¼8.8 Hz, 1H), 7.70 (d,
J¼2.0 Hz, 1H), 7.75 (dd, J1¼8.4 Hz, J2¼2.4 Hz, 1H), 8.54 (br,
1H), 9.17 (s, 1H), 9.91 (br, 1H); 13C NMR (100 MHz, CDCl3): δ
172.19, 164.75, 150.53 (2C), 133.65, 128.89, 128.66 (2C), 127.85
(2C), 127.79, 126.72, 124.12, 123.84, 122.31, 117.15, 109.99(2C),
56.01 (2C), 31.07, 9.64; HR-MS (ESI): m/z calcd. for
C17H17Cl2N2O3 367.06162, found: 367.06016 [M+H]
+.4.2.17. 3′,4′,5′-Trimethoxyphenyl 3-propionyloxy-4-
methoxybenzamide (2)
Reaction of M2 with 3,4,5-trimethoxybenzenamine afforded
product 2 as white solid. Yield, 27%. Mp: 155–157 1C.
1H NMR(CDCl3) δ: 1.20 (t, J¼7.6 Hz, 3H) , 2.57 (q, J¼7.6 Hz,
2H), 3.87 (s, 9H), 3.96 (s, 3H), 6.43 (s, 2H), 6.98 (d, J¼8.2 Hz,
1H), 7.76 (br, 1H), 7.90 (dd, J¼8.2, 1.8 Hz, 1H), 9.02 (s, 1H),
HR-MS(ESI) calcd. for C20H24N3O7 [M+H]
+, m/z¼390.15528,
found: 390.15739.
4.3. General procedure for the synthesis of compounds 1m–1o,
1p–1r, 5a–5d
Step 1: 3-nitro-3-methoxybenzoic acid (S4) or 3-nitro-substituted
benzosulfonic acid (S5 and S6) (5.0 mmol) was dissolved in
excess thionyl chloride (5 mL) with a catalytic volume of DMF
(0.5 mL) to afford crude acid chloride. To a solution of aniline or
heteroarylamine (6.0 mmol, 1.2 equiv.) and TEA (6.0 mmol,
1.2 equiv.) in dried DCM (60 mL) was added dropwise the
solution of above acid chloride obtained in dried DCM under
ice bath. The subsequent mixture was left at room temperature
after addition and stirred for 4–8 h. The reaction was stopped by
adding water, and the diluted mixture was washed twice with a
10% NaCl aqueous solution. The organic phase was dried over
anhydrous Na2SO4 and ﬁltered. The ﬁltrate was puriﬁed by silica
gel column chromatography to afford the pure nitrated intermedi-
atesM4-1–M4-3,M5-1,M5-2. The synthesis step for intermediate
M5-2 was carried out using sodium hydride as an acid-binding
agent at 20 1C in dried DMF.
4.3.1. 4′-Triﬂuoromethylphenyl 3-nitro-4-methoxybenzamide
(M4-1)
Reaction of 3-nitro-4-methoxybenzoic acid (S4) with thionyl
chloride afforded sticky 3-nitro-4-methoxybenzoyl chloride which
was used without further puriﬁcation for later reaction with 4-
triﬂuoroaniline to afford intermediate M4-1 as gray solid in yield
43%. MS (ESI): m/z 341.1 [M+H]+.
4.3.2. 4′,6′-Dimethoxypyrimidin-2-yl 3-nitro-4-
methoxybenzamide (M4-2)
Reaction of 3-nitro-4-methoxybenzoyl chloride with 2-amino-4,6-
dimethoxypyrimidine and NaH as acid binding reagent to afford
intermediate M4-2 as white solid in total yield 21%. 1H NMR
(DMSO-d6): δ 2.57 (s, 3H), 3.74 (s, 6H), 5.80 (s, 1H), 7.73 (d,
J¼8.0 Hz, 1H), 8.13 (dd, J2¼2.0 Hz, J1¼8.0 Hz, 1H), 8.49 (d,
J¼2.0 Hz, 1H); MS (ESI): m/z 355.4 [M+H]+.
4.3.3. 5′-Cyanopyridin-2-yl 3-nitro-4-methoxybenzamide (M4-3)
Reaction of 3-nitro-4-methoxybenzoyl chloride with 2-amino-5-
cyanopyridine afforded intermediate M4-3 as white solid in total
yield 47%. 1H NMR (CDCl3): δ 4.06 (s, 3H), 7.23 (d, J¼8.8 Hz,
1H), 8.05 (dd, J2¼2.0 Hz, J1¼8.8 Hz, 1H), 8.21 (d, J¼8.8 Hz,
1H), 8.49 (d, J¼2.0 Hz, 1H), 8.56 (d, J¼8.8 Hz, 1H), 8.61 (d,
J¼1.6 Hz, 1H), 9.14 (br, 1H, –NH).
4.3.4. 3′,4′,5′-Trimethoxyphenyl 3-nitro-4-
methylbenzenesulfonamide (M5-1)
Reaction of 3-nitro-4-methylbenenasulfonic acid (S5) with thionyl
chloride afforded sticky 3-nitro-4-methylbenzenesulfonyl chloride
which was directly used for reaction with 3,4,5-trimethoxyaniline
to afford intermediate M5-1 as white solid in total yield 36%.
Synthesis of novel substituted N-aryl benzamides as hA3G stabilizers and their inhibitory activities against hepatitis 3191H NMR (DMSO-d6): δ 2.55 (s, 3H), 3.55 (s, 3H), 3.65 (s, 6H),
6.39 (s, 2H), 7.70 (d, J¼8.0 Hz, 1H), 7.94 (dd, J1¼8.0 Hz,
J2¼2.0 Hz, 1H), 8.30 (d, J¼2.0 Hz, 1H), 10.30 (s, 1H); EI-MS:
m/z 382 (M). HR-MS (ESI): m/z calcd. for C16H19N2O7S
383.09130, found: 383.09030 [M+H]+.4.3.5. 4′,6′-Dimethoxypyrimidin-2-yl 3-nitro-4-
methylbenzenesulfonamide (M5-2)
Reaction of 3-nitro-4-methylbenzenesulfonyl chloride with 2-
amino-4,6-dimethoxypyrimidine to afford M5-2 as white solid in
yield 44%. 1H NMR (DMSO-d6): δ 2.57 (s, 3H), 3.74 (s, 6H), 5.80
(s, 1H), 7.73 (d, J¼8.0 Hz, 1H), 8.13 (dd, J2¼2.0 Hz, J1¼8.0 Hz,
1H), 8.49 (d, J¼2.0 Hz, 1H); MS (ESI): m/z 355.4 [M+H]+.
Step 2: To a solution of the nitrated intermediate (1.0 mmol)
from step 1 in methanol was added a catalytic amount of 10% Pd/
C (30 mg) and the resulting mixture was stirred until the reaction
was completed (about 3–8 h) with H2 under a pressure of 40–
50 barr. The mixture was ﬁltered and the ﬁltrate was concentrated
in vacuo to give the intermediates of M4-4–M4-6, M5-3 and M5-
4. M4-6 was used without further puriﬁcation for next step to
synthesize product 1r.4.3.6. 4′-Triﬂuoromethylphenyl 3-amino-4-methoxybenzamide
(M4-4)
1H NMR (DMSO-d6): δ 3.83 (s, 3H), 4.94 (s, 2H, D2O
exchanged), 6.89 (d, J¼8.8 Hz, 1H), 7.23 (m, 3H), 7.67 (d,
J¼8.8 Hz, 1H), 7.97 (d, J¼8.8 Hz, 2H), 10.27 (s, 1H, D2O
exchanged); MS (ESI): m/z 311[M+H]+.4.3.7. 4′,6′-Dimethoxypyrimidin-2-yl 3-amino-4-
methoxybenzamide (M4-5)
1H NMR (DMSO-d6): δ 3.82 (s, 3H), 3.85 (s, 6H), 4.88 (br, 2H),
5.92 (s, 1H), 6.84 (d, J¼9.2 Hz, 1H), 7.19 (d, J¼2.0 Hz, 1H),
7.22 (dd, J1¼9.2 Hz, J2¼2.0 Hz, 1H), 10.30 (s, 1H); MS (ESI):
m/z 325.1[M+H]+.4.3.8. 3′,4′,5′-Trimethoxyphenyl 3-amino-4-
methylbenzenesulfonamide (M5-3)
1H NMR (DMSO-d6): δ 2.03 (s, 3H), 3.54 (s, 3H), 3.64 (s, 6H),
5.33 (br, 2H, D2O exchangable), 6.37 (s, 2H), 6.85 (dd, J1¼8.0
Hz, J2¼2.0 Hz, 1H), 7.02 (d, J¼1.6 Hz, 1H), 7.04 (d, J¼8.0 Hz,
1H), 9.90 (s, 1H, D2O exchangable); MS (ESI): m/z 353.3
[M+H]+.4.3.9. 4′,6′-Dimethoxypyrimidin-2-yl 3-amino-4-
methylbenzenesulfonamide (M5-4)
1H NMR(CDCl3): δ 2.23 (s, 3H), 3.81 (s, 6H), 5.63 (s, 1H), 7.15
(d, J¼7.6 Hz, 1H), 7.40 (s, 1H), 7.44 (d, J¼8.0 Hz, 1H); MS
(EI): m/z 324 [M].
Step 3: To a solution of aminated intermediates (1.0 mmol)
from step 2 and TEA (1.2 mmol, 1.2 equiv) in DCM was added
acyl chloride or methyl iodide (1.3 mmol, 1.3 equiv). The resulting
reaction was stirred at room temperature until completion. Diluted
reaction mixture was rinsed with 0.5 M NaOH and subsequently
water. The organic phase was puriﬁed by silica gel chromato-
graphy to afford compounds 1m–1r and 5a–5d as white or off-
white solids with total yields of 14–26%.4.3.10. 4′-Triﬂuoromethylphenyl 3-propionamido-4-
methoxybenzamide (1m)
Reaction of M4-4 with propionyl chloride afforded product 1m as
white solid. Yield, 22%. Mp: 148–150 1C. 1H NMR (400 MHz,
CDCl3): δ 1.27 (t, J¼7.6 Hz, 3H), 2. 48 (q, J¼7.6 Hz, 2H), 4.03
(s, 3H), 7.04 (d, J¼8.4 Hz, 1H), 7.13 (d, J¼8.0 Hz, 2H), 7.52 (d,
J¼8.0 Hz, 2H), 7.80 (br, 1H), 7.99 (dd, J1¼8.4 Hz, J2¼2.0 Hz,
1H), 8.09 (d, J ¼2.0Hz, 1H), 8.82 (br, 1H); 13C NMR (100 MHz,
CDCl3): δ 172.44, 165.23, 150.48, 141.25, 127.44, 126.81,
126.19, 126.15, 126.04, 124.86 (2C), 119.82 (2C), 116.92,
110.14, 56.03, 31.00, 9.53; HR-MS (ESI): m/z calcd. for
C18H17F3N2NaO3 389.10890, found: 389.11085 [M+Na]
+.
4.3.11. 4′-Triﬂuoromethylphenyl 3-triﬂuoroacetamido-4-
methoxybenzamide (1n)
Reaction of M4-4 with triﬂuoroacetyl anhydride afforded product
1n as white solid. Yield, 14%. Mp: 177–179 1C. 1H NMR
(400 MHz, CDCl3): δ 4.03 (s, 3H), 7.08 (d, J¼8.8 Hz, 1H),
7.63 (d, J¼8.4 Hz, 2H), 7.79 (d, J¼8.4 Hz, 2H), 7.90
(d, J¼8.4 Hz, 1H), 7.97 (br, 1H), 8.61 (br, 1H), 8.82 (s, 1H);
13C NMR (100 MHz, CDCl3): δ 164.57, 156.17, 153.09, 142.83,
128.68, 126.55, 126.20, 125.90, 125.86, 123.19 (2C), 120.16 (2C),
113.86, 117.63, 111.80, 56.43; HR-MS (ESI): m/z calcd. for
C17H13F6N2O3 407.08304, found: 407.08389 [M+H]
+.
4.3.12. 4′-Triﬂuoromethylphenyl 3-(2-bromopropionamido)-4-
methoxybenzamide (1o)
Reaction of M4-4 with 2-bromopropionyl chloride afforded
product 1o as white solid. Yield, 18%. Mp:159–161 1C.
1H NMR (400 MHz, CDCl3): δ 1.99 (d, J¼7.2 Hz, 3H), 4.01
(s, 3H), 4. 48 (q, J¼7.2 Hz, 1H), 7.03 (d, J¼8.4 Hz, 1H), 7.61
(d, J¼8.4 Hz, 2H), 7.79 (d, J¼8.4 Hz, 2H), 7.84 (dd, J2¼2.0 Hz,
J1¼8.4 Hz, 1H), 8.12 (br, 1H), 8.74 (br, 1H), 8.85 (d, J¼1.6 Hz,
1H); 13C NMR (100 MHz, CDCl3): δ 167.62, 165.05, 151.05,
141.12, 126.83, 126.28, 126.24, 126.20, 125.85, 125.56, 122.76,
119.82 (2C), 116.91, 110.30, 56.26, 45.00, 22.84; HR-MS (ESI):
m/z calcd. for C18H17BrF3N2O3 445.03746, found: 445.04045
[M+H]+.
4.3.13. 4′,6′-Dimethoxypyrimidin-2-yl 3-(2-
bromopropionamido)-4-methoxybenzamide (1p)
Reaction of M4-5 with 2-bromopropionyl chloride afforded
product 1p as white solid. Yield, 12%. Mp: 77–79 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.73 (d, J¼6.8 Hz, 3H), 3.85 (s, 6H),
3.92 (s, 3H), 5.04 (q, J¼6.7 Hz, 1H), 5.95 (s, 1H), 7.14 (d,
J¼8.4 Hz, 1H), 7.75 (dd, J1¼8.4 Hz, J2¼2.0 Hz, 1H), 8.51 (s,
J¼2.0 Hz, 1H), 9.66 (s, 1H), 10.63 (s, 1H); 13C NMR (100 MHz,
CDCl3): δ 171.84, 167.40 (2C), 164.17, 156.13, 151.30, 126.96,
126.90, 125.83, 117.68, 110.19, 85.29, 56.26, 54.45 (2C), 45.17,
22.95; HR-MS (ESI): m/z calcd. for C17H20BrN4O5 439.06171,
found: 439.06632 [M+H]+.
4.3.14. 4′,6′-Dimethoxypyrimidin-2-yl 3-propionamido-4-
methoxybenzamide (1q)
Reaction of M4-5 with propionyl chloride afforded product 1q as
white solid. Yield, 26%. Mp: 87–89 1C. 1H NMR (400 MHz,
CDCl3): δ 1.28 (t, J¼7.6 Hz, 3H), 2.48 (q, J¼7.6 Hz, 2H), 3.97
(s, 3H), 4.08 (s, 6H), 7.00 (d, J¼8.4 Hz, 1H), 7.83 (s, 1H), 7.84
(dd, J2¼2.0 Hz, J1¼8.4 Hz, 1H), 8.95 (s, 1H); 13C NMR
(100 MHz, CDCl3): δ 172.22, 171.94 (2C), 164.32, 156.35,
150.61, 127.49, 127.05, 125.12, 117.39, 110.06, 85.44, 56.03,
Y. Li et al.32054.26 (2C), 31.02, 9.57; HR-MS (ESI): m/z calcd. for C17H21N4O5
361.15119, found: 361.15154 [M+H]+.
4.3.15. 5′-Cyanopyridin-2-yl 3-propionamido-4-
methoxybenzamide (1r)
Reaction of M4-6 with propionyl chloride afforded product 1r as
white solid. Yield, 11%. Mp: 169–171 1C. 1H NMR (400 MHz,
DMSO-d6): δ 1.07 (t, J¼7.6 Hz, 3H), 2.39 (q, J¼7.6 Hz, 2H),
3.91 (s, 3H), 7.13 (d, J¼8.8 Hz, 1H), 7.85 (dd, J2¼2.0 Hz,
J1¼8.8 Hz, 1H), 8.26 (dd, J2¼2.0 Hz, J1¼8.8 Hz, 1H), 8.32 (d,
J¼8.8 Hz, 1H), 8.60 (s, 1H), 8.83 (d, J¼2.0 Hz, 1H), 9.17 (s,
1H), 11.12 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 172.38,
167.11 (2C), 152.89, 127.83, 127.39, 127.22, 126.09, 124.52,
122.90, 122.61, 119.18, 110.61, 109.60, 56.00, 29.24, 9.72; HR-
MS(ESI): m/z calcd. for C17H17N4O3 325.13006, found:
325.12894 [M+H]+.
4.3.16. 3′,4′,5′-Trimethoxyphenyl 3-methylamino-4-
methylbenzenesulfonamide (5a)
Reaction ofM5-3 with methyl iodide afforded product 5a as white
solid. Yield, 17%. Mp: 143–145 1C. 1H NMR (400 MHz, CDCl3):
δ 2.21 (s, 3H), 3.13 (s, 3H), 3.74 (s, 6H), 3.83 (s, 3H), 6.31 (s,
2H), 6.87 (s, 1H), 6.94 (d, J¼7.6 Hz, 1H), 7.13 (d, J¼8.0 Hz,
1H); 13C NMR (100 MHz, CDCl3): δ 152.91 (2C), 144.87,
137.44, 137.40, 134.78, 130.48, 127.14, 117.84, 113.61, 104.75
(2C), 60.88, 56.11 (2C), 38.65, 17.46; HR-MS (ESI): m/z calcd.
for C17H23N2O5S 367.13277, found: 367.13261 [M+H]
+.
4.3.17. 3′,4′,5′-Trimethoxyphenyl 3-acetamido-4-
methylbenzenesulfonamide (5b)
Reaction of M5-3 with acetyl chloride afforded product 5b as
white solid. Yield, 18%. Mp: 242–245 1C. 1H NMR (400 MHz,
DMSO-d6): δ 2.07 (s, 3H), 2.23 (s, 3H), 3.30 (s, 3H), 3.64 (s, 6H),
5.05 (br, 2H), 6.38 (s, 2H), 7.36 (d, J¼8.0 Hz, 1H), 7.43 (dd,
J1¼8.0 Hz, J2¼2.0 Hz, 1H), 8.05 (s, 1H), 9.39 (s, 1H), 10.08 (s,
1H); 13C NMR (100 MHz, CDCl3): δ 168.60, 152.93 (2C),
137.13, 137.03, 135.97, 134.00, 133.64, 131.02, 122.77, 122.46,
97.73 (2C), 60.01, 55.68 (2C), 23.40, 17.96; HR-MS (ESI): m/z
calcd. for C18H22N2NaO6S 417.10963, found: 417.11079 [M
+Na]+.
4.3.18. 3′,4′,5′-Trimethoxyphenyl 3-propionamido-4-
methylbenzenesulfonamide (5c)
Reaction of M5-3 with propionyl chloride afforded product 5c as
white solid. Yield, 21%. Mp: 183–186 1C. 1H NMR (400 MHz,
CDCl3): δ 1.25 (t, J¼7.6 Hz, 3H), 2.28 (s, 3H), 2.43 (q, J¼7.6
Hz, 2H), 3.76 (s, 9H), 6.37 (s, 2H), 6.51 (br, 1H), 6.99 (br, 1H),
7.22 (d, 1H, J¼8.0 Hz), 7.41 (d, J¼7.6 Hz, 1H), 8.47 (s, 1H);
13C NMR (100 MHz, CDCl3): δ 172.10, 153.41 (2C), 137.27,
136.45, 132.24 (2C), 130.76 (2C), 123.82, 121.22, 100.02 (2C),
60.88, 56.12 (2C), 30.56, 17.95, 9.62; HR-MS (ESI): m/z calcd.
for C19H25N2O6S 409.14333, found: 409.14419 [M+H]
+.
4.3.19. 4′,6′-Dimethoxypyrimidin-2-yl 3-propionamido-4-
methylbenzenesulfonamide (5d)
Reaction of M5-4 with propionyl chloride afforded product 5d as
white solid. Yield, 24%. Mp: 188–191 1C. 1H NMR (400 MHz,
CDCl3): δ 1.25 (t, J¼7.2 Hz, 3H), 2.16-2.22 (q, J¼7.2 Hz, 2H),
3.99 (s, 6H), 6.10 (s, 1H), 7.03 (br, 2H), 7.37 (d, J¼8.0 Hz, 1H),
7.97 (d, J¼8.0 Hz, 1H), 8.61 (s, 1H); 13C NMR (125 MHz,
CDCl3): δ 172.83 (2C), 172.28, 155.13, 138.11, 136.27 (2C),130.89, 126.26, 123.81, 90.86, 55.11 (2C), 29.64, 18.56, 8.20;
HR-MS (ESI): m/z calcd. for C16H21N4O5S 381.12326, found:
381.12495 [M+H]+.4.3.20. Phenyl 3-(2-bromopropionamido)-4-methoxybenzamide
(4a)
Compound 4a was synthesized by acylation of the amino group at
the C3-position of compound 4 with 2-bromopropionyl chloride (a
total yield of 85% was obtained). Mp: 169–172 1C. 1H NMR
(400 MHz, CDCl3): δ 1.98 (d, J¼7.2 Hz, 3H), 3.99 (s, 3H ), 4.58
(q, J¼7.2 Hz, 1H), 7.01 (d, J¼8.4 Hz, 1H), 7.13 (t, J¼7.4 Hz,
1H), 7.36 (t, J¼8.0 Hz, 2H), 7.64 (d, J¼8.4 Hz, 2H), 7.82 (dd,
J1¼8.4 Hz, J2¼2.0 Hz, 1H), 7.88 (br, 1H), 8.73 (br, 1H), 8.50 (d,
J¼2.0 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 167.54, 164.93,
150.80, 138.00, 128.97 (2C), 127.46, 126.72, 125.43, 124.37,
120.35 (2C), 116.92, 110.23, 56.21, 54.07, 22.87; HR-MS
(ESI) m/z calcd. for C17H18BrN2O3 377.05008, found 377.05141
[M+H]+.4.3.21. 4′-Chlorophenyl 3-propionamido-4-
methoxybenzenesulfonamide (6)
Compound 6 was synthesized from 3-amino-4-methoxy-benzene-
sulfonic acid (S6). The impure intermediates M6 were obtained
after removal of solvents in vacuum and then were used for later
procedures without puriﬁcation to afford ﬁnal product 6 with a
total yield of 19%. Mp: 190–192 1C. 1H NMR (400 MHz, CDCl3):
δ 1.25 (t, J¼7.6 Hz, 3H), 2. 44 (q, J¼7.6 Hz, 2H), 3.90 (s, 3H),
6.82 (d, J¼8.4 Hz, 1H), 7.04 (d, J¼8.8 Hz, 2H), 7.18 (d,
J¼8.8 Hz, 2H), 7.43 (dd, J1¼8.4 Hz, J2¼2.4 Hz, 1H), 7.74 (br,
1H), 8.93 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 172.22, 150.89,
135.41, 130.92, 130.47, 129.26 (2C), 128.23, 123.92, 122.85 (2C),
118.02, 109.27, 56.14, 30.97,9.52; HR-MS (ESI): m/z calcd. for
C16H18ClN2O4S 369.06758, found: 369.06894 [M+H]
+.4.4. Cells, plasmids and reagents
Huh7.5 human liver cells were kindly provided by Vertex
Pharmaceuticals (Boston, MA), and were cultured in Dulbecco's
Modiﬁed Eagle's Medium, which was supplemented with 10%
inactivated fetal bovine serum and 1% penicillin-streptomycin.
The cells were cultured at 37 1C in 5% CO2, released with 0.05%
trypsin-EDTA and split twice a week. The plasmid pFL-J6/JFH/
JC1, which contains the full-length chimeric HCV cDNA, was
kindly provided by Vertex Pharmaceutical (Boston, MA).4.5. Biological assays
The Huh7.5 cells were seeded at a density of 3 104 cells/cm2.
After 24 h of incubation the cells were infected with an HCV viral
stock (about 45 IU per cell) and simultaneously treated with IFN-
α, the test compound, or the solvent control. The culture medium
was removed 96 h after inoculation, and the total intracellular
RNA and total intracellular proteins were extracted with a Qiagen
Kit according to kit instructions. The intracellular HCV RNA was
quantiﬁed using a one-step real time RT-PCR kit (Invitrogen).
Cytotoxicity was tested using the MTT assay, and the IC50 and
CC50 were calculated using the Reed & Muench methods. The
details for the antiviral assay and immunoblot experiments were
similar to those previously described by Peng et al22.
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